用于心理健康的氯胺酮疗法越来越受欢迎，但缺乏监管，因为一项针对退伍军人的研究显示了不同的结果并引起了专家的担忧。 Ketamine therapy for mental health gains popularity, but lacks regulation, as a study on veterans reveals mixed results and raises concerns among experts.
为治疗心理健康问题提供输液的氯胺酮经济见证了营利性诊所的激增，其收入在 2022 年达到 31 亿美元，预计到 2030 年将翻一番，达到 69 亿美元。 The ketamine economy, offering infusions for mental health issues, has witnessed a surge in for-profit clinics and revenues reaching $3.1 billion in 2022, projected to double to $6.9 billion by 2030. 尽管缺乏 FDA 批准用于精神健康治疗，但由于迫切需要针对抑郁症等疾病的有效解决方案，该药物在美国已变得越来越普遍。 Despite the lack of FDA approval for mental health treatment, the drug has become increasingly common in the US due to the desperate need for effective solutions for conditions such as depression. 氯胺酮的超说明书使用以及治疗方案的可变性（从低剂量到引起幻觉的剂量）引起了人们对其安全性和监管的担忧。 Ketamine's off-label use and the variability in treatment protocols, ranging from low-dosage to hallucination-inducing amounts, raise concerns about its safety and regulation.